Weldon Wilson named to Swiss Re Executive Board and CEO of Swiss Re Life & Health America Inc.
04 Sep 2003
The Swiss Re Board of Directors has appointed W. Weldon Wilson to its Group Executive Board and named him as CEO of Swiss Re's North American life and health operations.
Wilson has been with Swiss Re and previously Life Re, prior to its acquisition by Swiss Re, since 1991. Most recently he served as executive vice president and head of the business engineering services unit, and formerly served as general counsel for the Life & Health Business Group. In his new role, effective immediately, Wilson will report to Jacques Dubois, chairman, CEO and president of Swiss Re America Holding Corp., and chairman of Swiss Re Life & Health America Inc.
Wilson succeeds Chris C. Stroup who has decided to step down from his current position, allowing him to devote more time to his family. Stroup will remain with the company in a part-time position, focusing on strategic initiatives in Swiss Re's Life & Health Business Group.
"As we move forward, we will continue to strengthen our leadership position in North America and Weldon is an experienced veteran who brings an array of skills to his new role," said Dubois. "Chris has been an outstanding leader of our business and I'm pleased that Swiss Re will be able to continue to access Chris' broad experience in reinsurance."
Notes to editors
Swiss Re is a leading reinsurer and the world's largest life and health reinsurer. The company is global, operating from 70 offices in 30 countries. Since its foundation in 1863, Swiss Re has been in the reinsurance business. Swiss Re has three business groups: Property & Casualty, Life & Health and Financial Services. Swiss Re offers a wide range of traditional reinsurance products and related services, which are complemented by insurance-based corporate finance solutions and supplementary services. Swiss Re is rated "AA" by Standard & Poor's, "Aa1" by Moody's and "A++" by A.M. Best.
Contact:
Group Communications, New York
Stephen Dishart, tel. +1 212 317 5640
